Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, oph...
Abpro Holdings chairman Miles Suk resigns, stays on board
Miles Suk resigns as CEO of Abpro Holdings; M. Fatih Karatas named Interim CEO
Abpro net loss narrows 68% to $940,000 in Q2 FY26; revenue remains no revenue
Abpro Holdings Received Notice of Delisting